Yifan Pharmaceutical Co., Ltd

Yifan Pharmaceutical Co., Ltd. is a company listed on the A-share market of the Shenzhen Stock Exchange. Its stock abbreviation is Yifan Pharmaceutical, and its stock code is 002019. The company is an innovative pharmaceutical R&D and production enterprise. It has Yifan Research Institute, a national postdoctoral research station, and a provincial enterprise technology center (R&D center). It owns a number of technology companies and currently has more than 100 masters and doctors in pharmacy and related majors. , has two advanced biopharmaceutical innovation research and development platforms, bimolecular technology and immune antibody technology, and has been authorized nearly 100 international and domestic drug-related patents, including 35 international patents. The company has undertaken national "Tenth Five-Year Plan" research projects, national high-tech industrialization demonstration projects, and national torch plan projects, and has won the second prize of the National Invention Award and the second prize of the National Science and Technology Progress Award. Guided by product lines in professional, specialized and therapeutic key specialist areas, the company continues to innovate, transform and upgrade, and develop into key areas such as macromolecular biopharmaceuticals, high-end chemical drugs and specialty traditional Chinese medicines. It has dozens of high-end chemical drugs under research, nearly 10 of which are in the clinical or production stage; it has more than 400 drug approval numbers for gynecology, pediatrics, dermatology, etc., including more than 40 exclusive Chinese and Western medicines, and exclusive medical insurance varieties More than 20. Currently, there are several large molecule biopharmaceuticals in the international clinical phase II and III. It is the first Chinese company to enter phase II and phase III clinical trials of large molecule innovative biopharmaceuticals in the United States. It will lead Chinese biopharmaceuticals to make a breakthrough in the United States. door. The company has formed a production center for small molecule high-end chemical drugs and botanical drugs mainly in Anhui, a production center for dermatology and gynecological drugs mainly in Sichuan, a production center for orthopedic drugs and therapeutic large-scale infusion mainly in Liaoning, and a production center mainly in Beijing and A large molecule biopharmaceutical R&D and production center based in Shanghai and an API production center based in Zhejiang. The company's pharmaceutical business covers all provinces and municipalities except Hong Kong, Macao and Taiwan. The coverage rate of pharmaceutical preparations in second-level and above hospitals nationwide exceeds 60%. At the same time, as the world's largest production supplier of vitamin B5 and provitamin B5, the company sells medical raw materials The network radiates to many countries and regions such as Europe and the United States, with a global market share of 40%-45%, firmly occupying the leading position. Facing the future, the company will always focus on medicine and medical health, adhere to the development strategy of "integration, innovation, and internationalization", adhere to the core values ​​of "pragmatism, innovation, integrity, and diligence", and strive to create benefits for customers and employees. Create a platform to create wealth for shareholders, create value for society, and continue to grow into a global expert in the pharmaceutical and health industry.